MK-677vsTestagen

MK-677 (Ibutamoren) is a non-peptide spiropiperidine compound that functions as a potent, orally active agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). Unlike peptide-based GH secretagogues that require injection, MK-677 is resistant to gastrointestinal degradation and has excellent oral bioavailability, making it unique among compounds that stimulate GH release through the ghrelin receptor.

Upon binding GHS-R1a in the anterior pituitary, MK-677 activates the Gq/11-coupled PLC/IP3/calcium signaling pathway, triggering GH vesicle exocytosis. It also acts on GHS-R1a receptors in the hypothalamus, stimulating GHRH neurons in the arcuate nucleus while suppressing somatostatin tone, further amplifying the GH secretory signal. Importantly, MK-677 preserves the endogenous pulsatile pattern of GH release — it amplifies pulse amplitude rather than creating a flat, sustained elevation.

The 24-hour half-life means a single daily dose maintains elevated GH and IGF-1 levels around the clock. In clinical studies, MK-677 increased IGF-1 levels by 40-60% in elderly subjects, with sustained effects over 12 months without significant tachyphylaxis. However, its ghrelin-mimetic activity also activates hypothalamic appetite circuits (orexigenic neurons expressing NPY/AgRP), producing the notable increase in hunger that many users report. The compound also has mild cortisol-raising effects and can impair insulin sensitivity with prolonged use, likely through sustained GH-mediated antagonism of insulin signaling in peripheral tissues. Despite promising clinical data for muscle wasting and osteoporosis, MK-677 has not completed the FDA approval process.

Testagen is a short Khavinson tetrapeptide (Lys-Glu-Asp-Gly) positioned as the male reproductive and prostate tissue bioregulator within the wider Khavinson peptide family. The proposed mechanism is consistent with the family-wide model: short peptides interact with gene promoter regions in target tissue cells, modulating tissue-specific gene expression patterns to support normal cellular function and counteract age-related decline.

Proposed targets include genes regulating prostate epithelial proliferation and differentiation, androgen receptor signalling sensitivity, and local immune function within prostatic and testicular tissue. Russian research groups have reported testagen-induced improvements in indices of urinary and sexual function in elderly men with age-related prostatic and testicular decline, and animal studies have suggested effects on testicular function markers and prostate gland histology.

As with all Khavinson bioregulators, the published efficacy evidence sits almost entirely within Russian gerontology research traditions and has not been replicated in independent Western randomised controlled trials. Importantly, testagen is not validated for the prevention or treatment of prostate cancer or benign prostatic hyperplasia, and its safety in men with hormone-sensitive cancers has not been established. Use should not displace evidence-based urology care, and users with prostate concerns should consult a urologist rather than relying on bioregulator protocols.